Football chairman takes shine to Italian device firm:
This article was originally published in Clinica
Executive Summary
Italian entrepreneur Giuseppe Gazzoni Frascara is interested in purchasing implant manufacturer Officine Ortopediche Rizzoli, says Il Corriere della Sera. The main shareholders in the company are Istituto Rizzoli (70%), the Region of Emilia Romagna and the provincial and local authorities of Bologna (24%) and a group of private investors. Mr Gazzoni Frascara is chairman of Gazzoni SpA and of Bologna football club. His interest in the implant manufacturer is "personal".
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.